Nctid:
NCT06229964
Payload:
{"hasResults"=>false, "derivedSection"=>{"miscInfoModule"=>{"versionHolder"=>"2024-12-20"}, "conditionBrowseModule"=>{"meshes"=>[{"id"=>"D002062", "term"=>"Bursitis"}], "ancestors"=>[{"id"=>"D007592", "term"=>"Joint Diseases"}, {"id"=>"D009140", "term"=>"Musculoskeletal Diseases"}], "browseLeaves"=>[{"id"=>"M10621", "name"=>"Joint Diseases", "relevance"=>"LOW"}, {"id"=>"M5332", "name"=>"Bursitis", "asFound"=>"Frozen Shoulder", "relevance"=>"HIGH"}, {"id"=>"M12097", "name"=>"Musculoskeletal Diseases", "relevance"=>"LOW"}], "browseBranches"=>[{"name"=>"Musculoskeletal Diseases", "abbrev"=>"BC05"}, {"name"=>"All Conditions", "abbrev"=>"All"}]}, "interventionBrowseModule"=>{"browseLeaves"=>[{"id"=>"M11749", "name"=>"Methylprednisolone", "relevance"=>"LOW"}, {"id"=>"M1833", "name"=>"Methylprednisolone Acetate", "relevance"=>"LOW"}, {"id"=>"M11750", "name"=>"Methylprednisolone Hemisuccinate", "relevance"=>"LOW"}, {"id"=>"M14120", "name"=>"Prednisolone", "relevance"=>"LOW"}, {"id"=>"M229449", "name"=>"Prednisolone acetate", "relevance"=>"LOW"}, {"id"=>"M211887", "name"=>"Prednisolone hemisuccinate", "relevance"=>"LOW"}, {"id"=>"M248881", "name"=>"Prednisolone phosphate", "relevance"=>"LOW"}, {"id"=>"M1700", "name"=>"Ropivacaine", "relevance"=>"LOW"}], "browseBranches"=>[{"name"=>"Anti-Inflammatory Agents", "abbrev"=>"Infl"}, {"name"=>"Antiemetics", "abbrev"=>"AnEm"}, {"name"=>"Neuroprotective Agents", "abbrev"=>"NeuroAg"}, {"name"=>"Gastrointestinal Agents", "abbrev"=>"Gast"}, {"name"=>"All Drugs and Chemicals", "abbrev"=>"All"}, {"name"=>"Antineoplastic Agents", "abbrev"=>"ANeo"}, {"name"=>"Central Nervous System Depressants", "abbrev"=>"CNSDep"}]}}, "protocolSection"=>{"designModule"=>{"phases"=>["NA"], "studyType"=>"INTERVENTIONAL", "designInfo"=>{"allocation"=>"RANDOMIZED", "maskingInfo"=>{"masking"=>"QUADRUPLE", "whoMasked"=>["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"], "maskingDescription"=>"All patients will receive 2 concomitant injections: 1 IACI and 1 SSNB. Control group : sham SSNB is performed with a short-acting local anesthetic (Linisol 2%).\n\nIntervention group : SSNB is performed with a long-acting anesthestic (Ropivacaine 2%) + 40-mg methylprednisolone acetate.\n\nSame injected volume (5ml) in sham and intervention group. The advantage of using a short-acting anesthetic as a sham injection instead of a saline, is that at the time of injection the patient may perceive the anticipated short effect of the anesthetic similar to the intervention SSNB.\n\nThe care provider will be unaware of the type of SSNB of the allocation group. The outcomes assessor will be unaware of the type of SSNB of the allocation group.\n\nThe investigator who administers the injections, will be unaware of the allocation.\n\nThe investigational products will be prepared by the pharmacist according to a pre-defined co-variate constrained randomization key."}, "primaryPurpose"=>"TREATMENT", "interventionModel"=>"PARALLEL", "interventionModelDescription"=>"Prospective single-center Randomized Parallel-group"}, "enrollmentInfo"=>{"type"=>"ESTIMATED", "count"=>100}}, "statusModule"=>{"overallStatus"=>"NOT_YET_RECRUITING", "startDateStruct"=>{"date"=>"2024-04-01", "type"=>"ESTIMATED"}, "expandedAccessInfo"=>{"hasExpandedAccess"=>false}, "statusVerifiedDate"=>"2023-11", "completionDateStruct"=>{"date"=>"2027-04-01", "type"=>"ESTIMATED"}, "lastUpdateSubmitDate"=>"2024-02-08", "studyFirstSubmitDate"=>"2024-01-09", "studyFirstSubmitQcDate"=>"2024-01-25", "lastUpdatePostDateStruct"=>{"date"=>"2024-02-12", "type"=>"ACTUAL"}, "studyFirstPostDateStruct"=>{"date"=>"2024-01-29", "type"=>"ACTUAL"}, "primaryCompletionDateStruct"=>{"date"=>"2026-03-31", "type"=>"ESTIMATED"}}, "outcomesModule"=>{"otherOutcomes"=>[{"measure"=>"Superiority analysis of shoulder-related disability, pain and shoulder stiffness at 6 months.", "timeFrame"=>"6 months", "description"=>"An intermediary statistical analysis will be performed at 6 months. In case all 3 outcomes (disability, pain, shoulder stiffness) show non-superiority at 6m, the study will not be extended to the 12-month time point."}, {"measure"=>"Exploratory prediction analysis: part 1", "timeFrame"=>"18 months after inclusion", "description"=>"Through regression analysis the investigators want to find out which factors predict I) SPADI score at 3 -6- 12 months follow-up, II) pain NPR level at 3-6-12 months, III) shoulder ROM (°) at 3-6-12 months and IV) return to work and WAI score at 3-6-12 months.\n\nThe initial set of predictor variables, baseline values, that will be considered is :\n\n1. SPADI score\n2. Presence of joint capsule enhancement on MRI: (yes/no)\n3. Shoulder ROM (°)\n4. Age (years)\n5. Gender (male/female)\n\n5. Duration of symptoms to intervention (weeks) 6. Presence of diabetes (yes/no)"}, {"measure"=>"Exploratory prediction analysis: part 2", "timeFrame"=>"18 months after inclusion", "description"=>"Through regression analysis the investigators want to identify which physical examination tests, or which combinations of tests are correlated with MRI diagnostic criteria and a more positive evolution of SPADI score - NPR pain score - shoulder ROM (°)- Return to Work (RTW)/WAI score:\n\nThe initial set of predictor variables, baseline values, that will be considered is :\n\n1. SPADI score\n2. Presence of joint capsule enhancement on MRI: (yes/no)\n3. Shoulder ROM (°)\n4. Age (years)\n5. Gender (male/female)\n\n5. Duration of symptoms to intervention (weeks) 6. Presence of diabetes (yes/no)"}, {"measure"=>"Exploratory prediction analysis: part 3", "timeFrame"=>"18 months after inclusion", "description"=>"Through regression analysis the investigators want to identify patients that benefit the most from the combined SSNB + IACI\n\nThe initial set of predictor variables, baseline values, that will be considered is :\n\n1. SPADI score\n2. Presence of joint capsule enhancement on MRI: (yes/no)\n3. Shoulder ROM (°)\n4. Age (years)\n5. Gender (male/female)\n\n5. Duration of symptoms to intervention (weeks) 6. Presence of diabetes (yes/no)"}], "primaryOutcomes"=>[{"measure"=>"Shoulder Pain and Disability Index (SPADI)", "timeFrame"=>"3 months", "description"=>"The Shoulder Pain and Disability Index (SPADI) is a self-administered index consisting of 13 items, divided into two subscales: 5 items for pain and 8 items for disability. It can be completed by patients in less than 5 min and has shown good reliability and construct validity in the assessment of shoulder impairments and in particular frozen shoulder. The score for each subscale is obtained by adding up all the individual subscale scores and dividing the result by the maximum subscale score. The normalized score is converted to a scale from 0 to 100, with 100 indicating no problems and 0 indicating serious problems."}], "secondaryOutcomes"=>[{"measure"=>"Pain - Numeric Pain Rating Scale (NPRS)", "timeFrame"=>"4 weeks - 3 months - 6 months - 12months after the intervention", "description"=>"The Numerical Pain Rating Scale (NPRS) is a subjective measure in which individuals rate their pain on an eleven-point numerical scale. The scale is composed of 0 (no pain at all) to 10 (worst imaginable pain). It is the simplest and most commonly used pain rating scale and offers numerous advantages, including ease of administration and scoring, multiple response options, and no reported age-related difficulties in its use."}, {"measure"=>"Shoulder Pain and Disability Index (SPADI)", "timeFrame"=>"4 weeks- 6 months - 12months after the intervention", "description"=>"The Shoulder Pain and Disability Index (SPADI) is a self-administered index consisting of 13 items, divided into two subscales: 5 items for pain and 8 items for disability. It can be completed by patients in less than 5 min and has shown good reliability and construct validity in the assessment of shoulder impairments and in particular frozen shoulder. The score for each subscale is obtained by adding up all the individual subscale scores and dividing the result by the maximum subscale score. The normalized score is converted to a scale from 0 to 100, with 100 indicating no problems and 0 indicating serious problems."}, {"measure"=>"Constant- Murley score (CMS)", "timeFrame"=>"4weeks - 3 months - 6 months - 12 months after the intervention", "description"=>"The CMS is a composite scale divided into four sections: pain (15 points), activities of daily living (20 points), ROM (40 points) and strength (25 points) with a total score ranging from 0 (worst possible) to 100 (best possible). Patients were asked to verbally rate each parameter."}, {"measure"=>"Health related quality of life, evaluated with the EuroQol", "timeFrame"=>"4weeks - 3 months - 6 months - 12 months after the intervention", "description"=>"The EQ-5D 3L is a generic measure of health-related quality of life developed by the EuroQol Group. It is a validated measurement of quality of life widely used in different pathologies. The questionnaire is made up of two parts. The first part is descriptive and uses five different dimensions to score quality of life. These five dimensions are mobility, self-care, activities of the daily life, pain/discomfort and anxiety/depression. There are five different answer possibilities within each dimension, i.e. \"no problem\", \"slight problem\", \"moderate problem\", \"severe problem\" and \"unable to\". This renders 3125 different answer possibilities. The second part uses a visual analogue scale (VAS) to score the current health status of the patient, ranging from zero to one hundred. Zero corresponds to death and one hundred corresponds to a (subjective) perfect health status."}, {"measure"=>"PROMIS-29 Upper Extremity v2.0", "timeFrame"=>"4weeks - 3 months - 6 months - 12 months after the intervention", "description"=>"The nine-item Patient-Reported Outcomes Measurement Information System (PROMIS)- Upper Extremity short form has been validated against different legacy PROM and general health scores.\n\nItem-levels are scored numerically for an individual's response to each question.\n\nPROMIS instruments are always expressed as a score relative to the mean of a group (T-score). The mean score in a population is assigned the value 50. The standard deviation is equal to 10 points. Higher scores (above the mean score) means more of the concept being measured."}, {"measure"=>"Shoulder ROM in abduction, anteflexion, external rotation", "timeFrame"=>"4weeks - 3 months - 6 months - 12 months after the intervention", "description"=>"Active and passive ROM in anterior elevation, abduction and external rotation are measured using an adapted (large, total length 50cm) goniometer, as described by Riddle et al. and Sabari et al., and values were expressed in degrees °."}, {"measure"=>"Tampa Scale for Kinesiophobia (TSK-11):", "timeFrame"=>"4weeks - 3 months - 6 months - 12 months after the intervention", "description"=>"A shortened version of the original 17-item TSK, that measures the extent to which a person believes that physical activity or movement may lead to (re)-injury. Patients rate each item on a four-point Likert scale, with scoring alternatives ranging from \"strongly disagree\" to \"strongly agree\". Scores range from 11 to 44 with a higher score reflecting greater pain-related fear."}, {"measure"=>"Pain Self-Efficacy Questionnaire (PSEQ)", "timeFrame"=>"4weeks - 3months - 6 months - 12 months after the intervention", "description"=>"The Pain Self-Efficacy Questionnaire (PSEQ) is a 10-item scale which assesses a person's confidence in the ability to perform a task or activity, despite the pain. Each item is scored on a seven-point Likert scale (from \"not at all confident\" to \"completely confident\"). The total score ranges from 0 to 60 with a higher score representing greater pain self-efficacy beliefs."}, {"measure"=>"Global Rating of Change Score (GRoC)", "timeFrame"=>"4weeks - 3months - 6 months - 12 months after the intervention", "description"=>"The Global Rating of Change Score (GRoC) is a frequently used outcome measure that is used independently to measure improvements in a patient's condition or as an anchor for other outcomes measures. On 11-point Likert scale participants rate the clinical course of their condition since the start of the treatment: from -5 \"a great deal worse\" to +5 \"a great deal better\" with 0 being \"no change\"."}, {"measure"=>"Work Ability Index (WAI)", "timeFrame"=>"4weeks - 3months - 6 months - 12 months after the intervention", "description"=>"The Work Ability Index (WAI) measures the work ability considering physical and mental parts of work as well as different diseases and their impact on work ability. It's a 10 items questionnaire concerning current work ability compared with the lifetime best, work ability in relation to the job demands, number of current diseases diagnosed by a physician, estimated work impairment due to diseases, sick leave, self-prognosis of work ability and mental resources.\n\nA given answer to a question earns points. The sum of all these points results in the WAI score, which ranges from 7 to 49 points. The score indicates the extent to which the individual's capabilities and the job requirements are consistent with each other, a higher score indicating a better match between capabilities and job requirements."}, {"measure"=>"Work Status", "timeFrame"=>"4weeks - 3months - 6 months - 12 months after the intervention", "description"=>"Work status: Health economic assessment: As the investigators expect subgroups of Frozen Shoulder to be unable to work, subjects will be questioned if they are incapacitated to work due to Frozen Shoulder during baseline assessments. Once the symptoms and function improve, the investigators expect patients to be able to return to work."}, {"measure"=>"Health care service use", "timeFrame"=>"4weeks - 3months - 6 months - 12 months after the intervention", "description"=>"Patients will keep a diary to log usage of pain medication and physiotherapy visits"}, {"measure"=>"Adverse effects", "timeFrame"=>"4weeks - 3months - 6 months - 12 months after the intervention", "description"=>"At every patient study contact, the occurrence or not of adverse affects will be recorded."}, {"measure"=>"Rescue therapy", "timeFrame"=>"3months - 6months - 12months after the intervention", "description"=>"As this is a pragmatic trial, patients will be offered rescue therapy, consisting of an USG SSNB + IACI in their affected shoulder, every 3 months after inclusion, with a maximum of 3 interventions in 12 months"}]}, "oversightModule"=>{"isUsExport"=>false, "oversightHasDmc"=>true, "isFdaRegulatedDrug"=>false, "isFdaRegulatedDevice"=>false}, "conditionsModule"=>{"keywords"=>["Frozen Shoulder", "Adhesive Capsulitis of the Shoulder", "Intra-articular corticosteroid injection", "ultra-sound guided injection", "suprascapular nerve block", "Joint Diseases", "Musculoskeletal Diseases", "Bursitis"], "conditions"=>["Frozen Shoulder", "Adhesive Capsulitis"]}, "descriptionModule"=>{"briefSummary"=>"Frozen shoulder remains a challenging disease to treat as pain and loss of range of motion can persist for many months or even years. This loss of function can have a severe impact on the patient's activities, participation and overall quality of life.\n\nThe use of ultrasound-guided (USG) suprascapular nerve blocks (SSNB) and/or intra-articular corticoid injections (IACI) has been supported by many studies. However, double blinded randomized clinical trials using a combination of SSNB and IACI are rare.\n\nThe primary objective of this study is to compare the effectiveness of a glenohumeral IACI combined with a SSNB, compared to a glenohumeral IACI combined with a sham SSNB. Outcome measures of interest are shoulder-related disability reported by the patients, shoulder pain and shoulder stiffness. These outcome parameters will be compared between both treatment arms with an intention-to-treat analysis.\n\nAs key secondary objectives, the investigators aim to identify which physical examination tests, or combinations of those, are correlated with MRI diagnostic criteria and favor a more positive evolution. Finally, through predictive analysis the investigators will try to establish which patients benefit the most from the combined SSNB + IACI.", "detailedDescription"=>"Frozen Shoulder (FS) is common disease affecting 2 to 5% of the general population, with a higher prevalence in patients suffering from diabetes and thyroid dysfunction.It remains frustrating for patients and treating health care professionals as severe shoulder pain and loss of function can last for up to two years. 5-7 In the early stage, most patients identify the following symptoms: strong component of night pain, pain with rapid or unguarded movements and aggravated by movement or lying on the affected shoulder.8 Combined with marked pain and limitation in all directions of shoulder range of motion, it is easy to understand that suffering from Frozen Shoulder will have a detrimental effect on quality of life and the ability to perform activities of daily living.\n\nThe overall treatment aim for this condition is to \"improve pain and function\" and treatment goals should be set individually in a shared decision-making process. Patient education on the clinical course and different possible therapeutic interventions, including self-management strategies, should always come first. Clinicians should promote activity modification to utilize pain-free, functional ROM and stretching of the shoulder capsule matching the patient's current level of irritability.\n\nIntra-articular corticosteroid injections (IACI) into the gleno-humeral (GH) joint, combined with shoulder mobility and stretching exercises, have shown to be more effective in providing short-term (4-6weeks) pain relief and improved function compared to exercises alone.\n\nA recent article by Rex et al. places the results of the UK FROST trial in the context of 8 other randomized controlled trials comparing intra-articular corticoid injections (IACI) to manipulation under anesthesia (MUA), arthroscopic capsular release (ACR) and hydrodilatation. These findings did not show clinical superiority of either IACI, MUA nor ACR and evidence for hydrodilatation was inconclusive.\n\nCommon sense, in accordance with the National Institute of Health and Care Excellence (NICE) guidelines, recommends that treatments should be offered in a stepped approach from least to most invasive. In their systematic review from 2020, Challoumas et al. show that in the early phase of Frozen Shoulder IA corticosteroid is associated with better short-term outcomes, with possible benefits extending in the mid-terms. These authors recommend to associate IACI to education for home-based exercises and physiotherapy to increase the chances of resolution of symptoms by 6 months.\n\nUnfortunately, not all patients show sufficient improvement in pain and function with IACI and need other therapies. The suprascapular nerve (SSN) provides 60 tot 70% of sensory innervation of the shoulder and suprascapular nerve block (SSNB) has shown in meta-analysis to significantly improve pain and ROM in patients with Frozen Shoulder. This systematic review however has several limitations. Blinding was not always sufficient to rule out a placebo effect, different injections techniques and products (local anesthetics with or without corticosteroids) were used and only data for pain and ROM shoulder could be aggregated as shoulder function was not evaluated in enough trials.\n\nIn a rigorous triple blinded RCT, we demonstrated that three successive SSNB with local anesthetics did not improve shoulder pain and function more than three sham injections in patients suffering from subacute Frozen Shoulder. On the other hand, it has been hypothesized that the SSN may be involved in the pathogenesis of Frozen Shoulder and that therefore using optimal approach and drugs (combination of local anesthetics and corticosteroids) in SSNB should be further evaluated in high-quality RCTs.\n\nIn a retrospective review of 102 patients, Jung et al. showed that the combination of an IACI with an SSNB further increased treatment efficacy compared to a single IACI in Frozen Shoulder patients; as pain, ROM and function scored significantly better at different time points (2weeks, 2months and 1 year).\n\nTo our knowledge, there has been no previous prospective RCT investigating the added value of an SSNB in combination with an IACI, delivering under ultra-sound guidance the same total amount of corticosteroids in both treatment arms and assuring quadruple blinding (participant, care provider, investigator and outcomes assessor).\n\nThe aim of this study is to determine if there is any difference in pain relief and function, as measured by the Shoulder Pain and Disability Index (SPADI), in patients with Frozen Shoulder when given an GH IACI with a SSNB compared to an GH IACI with a sham SSNB. Furthermore, we want to identify which patients will benefit most from GH IACI or the combination of GH IACI and SSNB. The results of this trial will help to guide clinical practice treating patients with FS and improve resource allocation."}, "eligibilityModule"=>{"sex"=>"ALL", "stdAges"=>["ADULT", "OLDER_ADULT"], "maximumAge"=>"99 years", "minimumAge"=>"18 years", "healthyVolunteers"=>false, "eligibilityCriteria"=>"Inclusion Criteria:\n\n* Written informed consent to participate in the study must be obtained from the subject prior to initiation of any study-mandated procedure\n* Suffering from Frozen Shoulder, defined as: Frozen shoulder is a self-limiting disease characterized by pain and functional restriction in both active and passive shoulder motion lasting more than 1 month, for which radiographic findings of the shoulder joint are unremarkable.\n* Dutch or French speaking persons\n* Age ≥ 18 years\n\nExclusion Criteria:\n\n* Subjects with posttraumatic or postsurgical stiff shoulder syndrome\n* History of trauma at the onset of symptoms\n* Subjects with rheumatologic or neurologic disease involving the shoulder\n* Subjects with cervical radiculopathy\n* Coagulation disorder\n* Hypersensitivity to local anesthetics or MRI contrast agent\n* Inability to understand the study procedures\n* Psychiatric illness\n* Pregnancy\n* Subjects who have received prior SSNB in the homolateral shoulder\n* Subjects who have received an IACI in the homolateral shoulder in the 3 months before inclusion"}, "identificationModule"=>{"nctId"=>"NCT06229964", "acronym"=>"FROSTBLOCK", "briefTitle"=>"Frozen Shoulder Treatment With Intra-Articular Corticosteroid Injection and Suprascapular Nerve Block", "organization"=>{"class"=>"OTHER", "fullName"=>"Universitair Ziekenhuis Brussel"}, "officialTitle"=>"A Double Blinded Randomized Controlled Trial (RCT) Exploring the Additional Effect of a Suprascapular Nerve Block in Combination With an Intra-Articular Corticosteroid Injection in Patients With Frozen Shoulder", "orgStudyIdInfo"=>{"id"=>"23454_FROSTBLOCK"}}, "armsInterventionsModule"=>{"armGroups"=>[{"type"=>"ACTIVE_COMPARATOR", "label"=>"SSNB + IACI", "description"=>"Patients randomized to this arm will receive a SSNB (40-mg methylprednisolone acetate and 5-mL Ropivacaine 2mg/ml) than a IACI (40-mg methylprednisolone acetate and 1-mL Ropivacaine 2mg/ml).\n\nRehabilitation/physiotherapy is considered standard of care.", "interventionNames"=>["Other: SSNB + IACI"]}, {"type"=>"PLACEBO_COMPARATOR", "label"=>"Sham SSNB + IACI", "description"=>"Patients randomized to this arm will receive a SSNB (5-mL Linisol 10mg/ml) than a IACI (80-mg methylprednisolone acetate and 1-mL Ropivacaine 2mg/ml)\n\nRehabilitation/physiotherapy is considered standard of care.", "interventionNames"=>["Other: Sham SSNB + IACI"]}], "interventions"=>[{"name"=>"SSNB + IACI", "type"=>"OTHER", "otherNames"=>["Usual care"], "description"=>"Usual care: All patients complete rehabilitation under supervision of their own physiotherapist. The investigators will provide some guidelines and criteria but is the physiotherapist's choice how to implement these guidelines in clinical practice.\n\nPatient education on home-exercises Monitoring of peak pain, at rest/night and after rehabilitation sessions using a Numeric-Pain-Rating-Scale (0-10) (NPRS) to evaluate tissue irritability and guide physiotherapy and rehabilitation.\n\nUse of passive physiotherapy (cold, heat or electric therapies) to treat pain. Active and passive mobilization of the shoulder under the pain threshold, Maitland mobilization, stretch exercises such as: table slides, wall climbers. Use of affected upper limb in pain free Range-of-Motion (ROM) is tolerated and stimulated. Progressively increase time and frequency of Total-End-Range-Time (TERT) positions to increase ROM", "armGroupLabels"=>["SSNB + IACI"]}, {"name"=>"Sham SSNB + IACI", "type"=>"OTHER", "otherNames"=>["Usual care"], "description"=>"Usual care: All patients complete rehabilitation under supervision of their own physiotherapist. The investigators will provide some guidelines and criteria but is the physiotherapist's choice how to implement these guidelines in clinical practice.\n\nPatient education on home-exercises Monitoring of peak pain, at rest/night and after rehabilitation sessions using a Numeric-Pain-Rating-Scale (0-10) (NPRS) to evaluate tissue irritability and guide physiotherapy and rehabilitation.\n\nUse of passive physiotherapy (cold, heat or electric therapies) to treat pain. Active and passive mobilization of the shoulder under the pain threshold, Maitland mobilization, stretch exercises such as: table slides, wall climbers. Use of affected upper limb in pain free Range-of-Motion (ROM) is tolerated and stimulated. Progressively increase time and frequency of Total-End-Range-Time (TERT) positions to increase ROM", "armGroupLabels"=>["Sham SSNB + IACI"]}]}, "contactsLocationsModule"=>{"centralContacts"=>[{"name"=>"Marc Schiltz, MD", "role"=>"CONTACT", "email"=>"marc.schiltz@uzbrussel.be", "phone"=>"+324777712"}], "overallOfficials"=>[{"name"=>"Marc Schiltz, MD", "role"=>"PRINCIPAL_INVESTIGATOR", "affiliation"=>"Universitair Ziekenhuis Brussel"}]}, "ipdSharingStatementModule"=>{"ipdSharing"=>"NO", "description"=>"Data will be published in peer review journal on completion of the study."}, "sponsorCollaboratorsModule"=>{"leadSponsor"=>{"name"=>"Universitair Ziekenhuis Brussel", "class"=>"OTHER"}, "responsibleParty"=>{"type"=>"SPONSOR"}}}}
